Evidence mapPaperPMID 42550413Full record

ReviewClinical and experimental nephrology2026

Energy metabolism in the kidney and its role in chronic kidney disease.

Hiroaki Kikuchi, Tomohiro Tsuboya, Jinming Hu, Mari Sugimoto, Miyu Yoshikawa, Maho Usui, Takefumi Suzuki, Mark A Knepper, Shinichi Uchida, Eisei Sohara

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hiroaki KikuchiDepartment of Nephrology, Institute of Science Tokyo, Tokyo, Japan. hiroaki.k1114@gmail.com.ORCID http://orcid.org/0000-0001-7722-4131
Tomohiro TsuboyaDepartment of Nephrology, Institute of Science Tokyo, Tokyo, Japan.
Jinming HuDepartment of Nephrology, Institute of Science Tokyo, Tokyo, Japan.
Mari SugimotoDepartment of Nephrology, Institute of Science Tokyo, Tokyo, Japan.
Miyu YoshikawaDepartment of Nephrology, Institute of Science Tokyo, Tokyo, Japan.
Maho UsuiDepartment of Nephrology, Institute of Science Tokyo, Tokyo, Japan.
Takefumi SuzukiDepartment of Nephrology, Institute of Science Tokyo, Tokyo, Japan.
Mark A KnepperEpithelial Systems Biology Laboratory, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA.
Shinichi UchidaDepartment of Nephrology, Institute of Science Tokyo, Tokyo, Japan.
Eisei SoharaDepartment of Nephrology, Institute of Science Tokyo, Tokyo, Japan.

Funding

MSD Life Science Foundation, Public Interest Incorporated Foundation MSD Life Science Foundation, Public Interest Incorporated FoundationSenri Life Science Foundation Senri Life Science FoundationTakeda Foundation Takeda FoundationUehara Memorial Foundation Uehara Memorial Foundation
6 · The paper itself

Abstract

Chronic kidney disease (CKD) is associated with dysregulated lipid metabolism, particularly in proximal kidney tubules, where fatty acid oxidation serves as the primary energy source. The proximal tubules' reliance on fatty acid oxidation rather than glycolysis underscores their unique metabolic profile, consistent with the absence of key glycolytic enzymes. This dysregulation contributes to maladaptive hypertrophy in CKD, where surviving nephrons exhibit compensatory hypertrophy to maintain kidney function. Here, we focus on two key regulators of lipid metabolism: peroxisome proliferator-activated receptor alpha (PPARα) and adenosine monophosphate (AMP)-activated protein kinase (AMPK). Recent multi-omics studies have identified PPARα as an important determinant of proximal tubule cell size and a mediator of compensatory hypertrophy. In CKD models, AMPK activity decreases, impairing cellular responses to energy stress, as indicated by altered AMP/ATP ratios. This defective energy sensing may be exacerbated by uremic metabolites that diminish AMPK function. Unc-51-like autophagy activating kinase 1 (ULK1) has been identified as a regulator of AMPK activity through specific phosphorylation sites that enhance AMP sensitivity. Future research should assess whether targeting these pathways restores metabolic homeostasis and mitigates CKD progression by enhancing AMPK activity and lipid metabolism.

Indexed as

AMP-activated protein kinaseChronic kidney diseaseCompensatory renal hypertrophyKidneyNephronPeroxisome proliferator–activated receptor alphaProximal tubuleunc-51 like autophagy activating kinase 1

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.